Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues - pharmaceuticalcommerce.com
Novo Nordisk's Bloomington plant received an FDA Official Action Indicated (OAI) designation following contamination and compliance issues, signaling potential regulatory enforcement and supply chain disruptions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that rely on Novo Nordisk's Bloomington plant or are subject to similar FDA scrutiny. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate review recommended; no specific deadline provided.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA has classified the Bloomington plant as OAI, indicating significant compliance failures and potential for regulatory action.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that rely on Novo Nordisk's Bloomington plant or are subject to similar FDA scrutiny.
What you must do
Assess supply chain dependencies on the Bloomington plant and review internal compliance programs to ensure alignment with FDA expectations.
Deadline
Immediate review recommended; no specific deadline provided.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Uyghur Forced Labor Prevention Act Entity List
- Final Debarment Order: Ricardo Andres Acuna
- Final Debarment Order: Angela Anatilde Baquero
- Guidance: Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
- Guidance: Assessing Adhesion with Transdermal and Topical Delivery Systems for Abbreviated New Drug Applications